Literature DB >> 17234410

Discovery of thienopyridines as Src-family selective Lck inhibitors.

Lily Abbott1, Patrick Betschmann, Andrew Burchat, David J Calderwood, Heather Davis, Peter Hrnciar, Gavin C Hirst, Biqin Li, Michael Morytko, Kelly Mullen, Bryant Yang.   

Abstract

We describe the identification, SAR, and in vivo pharmacology of a new series of Src-family selective Lck inhibitors. These thienopyridines were designed based on a desire to access the unique residues in the extended hinge region of Lck.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17234410     DOI: 10.1016/j.bmcl.2006.12.035

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  4 in total

1.  HTRF: A technology tailored for drug discovery - a review of theoretical aspects and recent applications.

Authors:  François Degorce; Amy Card; Sharon Soh; Eric Trinquet; Glenn P Knapik; Bing Xie
Journal:  Curr Chem Genomics       Date:  2009-05-28

2.  Highly specific, bisubstrate-competitive Src inhibitors from DNA-templated macrocycles.

Authors:  George Georghiou; Ralph E Kleiner; Michael Pulkoski-Gross; David R Liu; Markus A Seeliger
Journal:  Nat Chem Biol       Date:  2012-02-19       Impact factor: 15.040

3.  New horizons in drug discovery of lymphocyte-specific protein tyrosine kinase (Lck) inhibitors: a decade review (2011-2021) focussing on structure-activity relationship (SAR) and docking insights.

Authors:  Ahmed Elkamhawy; Eslam M H Ali; Kyeong Lee
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

4.  Kinase inhibitors for the treatment of inflammatory and autoimmune disorders.

Authors:  Shripad S Bhagwat
Journal:  Purinergic Signal       Date:  2008-06-21       Impact factor: 3.765

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.